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The discovery of anaplastic lymphoma kinase (ALK ) rearrangement in non-small cell lung cancer
(NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK -rearranged
NSCLC in 2011 represents a landmark in the development of targeted oncology therapy. The
approval of crizotinib was accompanied simultaneously by the approval of the Vysis (Abbott
Molecular) break-apart fluorescence in situ hybridization (FISH) test as the companion diagnos-
tic (CDx) test to detect ALK rearrangement. Pfizer, the manufacturer of crizotinib, sponsored
the screening of thousands of patients and the standardization of the ALK FISH test as part
of the approval process for crizotinib, a first in class ALK inhibitor. Many pharmaceutical com-
panies are now using the Food and Drug Administration (FDA)-approved ALK FISH assay to
enroll patients onto trials for their own respective ALK inhibitors. In essence they are “piggy-
backing” on the FDA-approved ALK FISH assay without having to pay for the development of
a CDx, nor screening for ALK -rearranged NSCLC patients in the protocols because screening
for ALK rearrangement is now the standard of care in NSCLC after the approval of crizotinib.
Since 2007, rearrangement in more receptor tyrosine kinases (RTKs) such as ROS1, RET, AXL,
PDGFR-α, and NTRK1 have been discovered in NSCLC but the incidence of each subtype of
RTK-rearranged NSCLC is quite rare. Crizotinib has now demonstrated significant clinical activ-
ity in ROS1-rearranged NSCLC patients. Whether crizotinib will gain official FDA approval for
use in ROS1-rearranged NSCLC, on the other hand, remains unclear as there is no test for
ROS1-rearrangement currently being developed to support US FDA approval as a CDx.This may
be due in part to the fact that the full cost associated with the development of a pre-market
approved-approved CDx must be borne by the company seeking the first drug approval in a
new indication. Given the low incidence of ROS1-rearrangement in NSCLC, and the availability
of crizotinib in most countries, a more cost-effective way is for crizotinib to gain compendium
listing for ROS1-rearranged NSCLC in treatment guidelines. However, without a formal indica-
tion from the FDA, a drug cannot be marketed for off label use, it is unlikely that payers public
or private will routinely pay for molecular testing for ROS1-rearrangement in NSCLC let alone
reimburse off label use of crizotinib. Similarly, several marketed tyrosine kinase inhibitors (TKIs)
in the US (sorafenib, sunitinib, vandetanib, cabozantinib, regorafenib) are potent RET inhibitors
in vitro. It does not make sense for any one pharmaceutical company to shoulder the full cost
of developing a particular CDx for RET -rearranged NSCLC where, once approved, it may be
used by other pharmaceutical companies to gain addition labeling approval for their own RET
inhibitors.Thus, the requirement by the US FDA that a specific CDx have to be co-developed and
standardized for each of the molecular subtype of NSCLC as part of the drug approval process,
while prudent, may have the un-intended consequence of deterring clinical development of
theseTKIs in these very rare molecular subsets of NSCLC. While we all march to the drumbeat
of precision cancer medicine, the stringent requirement of co-development CDx for each mol-
ecular subtype of solid tumor may inadvertently make this goal substantially more difficult to
achieve.
Keywords: companion diagnostics, ALK -rearranged NSCLC, ROS1-rearranged NSCLC, RET -rearranged NSCLC,
fluorescence in situ hybridization, immunohistochemistry, next generation sequencing, reverse transcription-
polymerase chain reaction
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INTRODUCTION
Achieving personalized medicine is the “holy grail” in oncology.
The approval of crizotinib in the US, an anaplastic lymphoma
kinase (ALK)/ROS1/MET multi-targeted tyrosine kinase inhibitor
(TKI), merely 4 years after the discovery of rearrangement in ALK
in non-small cell lung cancer (NSCLC) represented a landmark in
oncology drug development and a significant step toward the goal
of personalized medicine in oncology (1). The approval of crizo-
tinib was accompanied the simultaneous approval of the Vysis
(Abbott Molecular) break-apart fluorescence in situ hybridization
(FISH) companion diagnostics (CDx) assay by the US Food and
Drug Administration (FDA) for the detection of ALK rearrange-
ment in NSCLC. The success of crizotinib has shone a bright
spotlight on the existence of molecular subsets of NSCLC and
other epithelial malignancies that are driven by rearrangement
in receptor tyrosine kinases (RTKs) and heralded the era of
RTK rearrangement in solid tumor oncology. Since 2007 other
RTK-rearrangements in NSCLC have been discovered (Table 1).
Concurrently, various diagnostic tests besides FISH have been
offered by major commercial diagnostic companies in the US
to detect the different RTK-rearrangements. Given the rarity of
RTK rearrangement in NSCLC and the requirement by US FDA to
develop an analytically and clinically validated CDx for approval
of TKIs against each RTK-rearranged molecular cohort, challenges
abound in persuading many pharmaceutical companies to pursue
a simultaneous registration strategy. We will review the lessons
learned from the development of crizotinib for ALK -rearranged
NSCLC where several second generation ALK inhibitors are in now
development due to the existence of an FDA-approved CDx, the
ongoing challenges in gaining additional FDA approval for crizo-
tinib in the treatment of ROS1-rearranged NSCLC due to a lack
of an approved CDx for ROS1-rearranged NSCLC, the immense
challenges in gaining approval for any currently marketed TKI that
are also potential RET TKI for the treatment of RET -rearranged
NSCLC due to again the lack of an FDA-approved CDx for RET
rearrangement (Table 2). Additionally, we will discuss whether
the first FDA-approved CDx is the optimal CDx going forward
given the inevitability of technology obsolescence coupled with
the exponential gain in knowledge in the understanding of these
subsets of molecularly defined NSCLC. Finally, we speculate that if
the current challenges of co-CDx approval are not overcame how
the development of precision cancer medicine may be impeded.
THE DISCOVERY OF RECEPTOR TYROSINE
KINASE-REARRANGED (ALK-, ROS1-, RET-, AXL-, PDGFR-α-,
NTRK1-) NSCLC
All the RTK-rearrangements identified in NSCLC occur in genes
of the human RTK family, which consists of 58 members (11). The
discovery of ALK rearrangement in NSCLC in 2007 was signifi-
cant because prior to the discovery it was believed that gene fusions
especially involving RTK rearrangement were believed to be rare in
epithelial tumors (12). It is abundantly clear that each subtype of
RTK-rearranged NSCLC is itself a heterogeneous disease made up
many different (and yet to be discovered) fusion partners translo-
cated to the same RTK (Table 1). The complexity within each
molecular subtype of RTK-rearranged NSCLC have implications
on the CDx. Ideally a CDx should be technically simple and/or
be easily standardized, cost-effective, but also provide “forward-
looking” information such as the exact fusion variant with at
the exact breakpoint so that subtle differences among the various
fusion variants within each molecular subtype of RTK-rearranged
NSCLC can be elucidated.
Rearrangement of ROS1 in NSCLC was discovered contempo-
raneously in 2007 by one of the two groups that discovered ALK
rearrangement (13). ROS1 shares extensive amino acid sequence
homology with ALK in particular within the kinase domain
making ROS1 a potential target for ALK inhibitors (14). Prior
to 2007, ROS1-rearrangement was discovered in glioblastoma
multiforme (15) and subsequently has been discovered in other
major epithelial tumor types including gastric (16) and colorectal
adenocarcinoma (17).
TheRET (rearranged during transfection) proto-oncogene was
first identified in 1985 through transfection of NIH3T3 cells with
human lymphoma DNA (18). RET rearrangement has also been
well characterized in thyroid cancer (19). Since 2012, multiple
groups using various techniques published the rearrangement of
RET in NSCLC with four identified fusion partners so far (KIF5B-
CCDC6-, NOCA4-, TRIM33-) (2) (Table 1).
Rearrangement of the tropomyosin-related kinase gene
(TRKA) was first biologically characterized in 1986 in a colorec-
tal carcinoma patient (20), when tropomyosin was found to be
fused to an unknown DNA sequence that likely codes for a trans-
membrane RTK (TPM3-TRKA) (20). The normal function of
TRKA is the receptor for neurotrophins and is responsible for
differentiation into subtypes of sensory neurons. TRKA has been
renamed as neurotrophic tyrosine receptor kinase 1 (NTRK1)
as it is one of three members of NTRK family (21). In 2013,
rearrangement in NTRK1 was reported in NSCLC involving fusion
partners with CD74 and MPRIP as fusion partners (CD74-NTRK1,
MPRIP-NTRK1) (4). Screening a panel of NSCLC that are pan-
negative for oncogenic driver mutations, they found 3 out of 91
(3.3%) were positive for NTRK1 rearrangement. Cell-based and
xenograft assays using NTRK1 inhibitors in NTRK1 transformed
cells led to inhibition of cellular proliferation and tumor shrinkage,
respectively, indicated NTRK1 rearrangement are indeed a driver
mutation in NSCLC (4). Of note similar to RET, rearrangement
of NTRK1 has been described in thyroid cancer (TPM3-NTRK1,
TPR-NTRK1, TFG-NTRK1) (22).
AXL, termed from the Greek word anexelekto, or uncontrolled,
was identified initially as a transforming oncogene in two chronic
myelogeneous leukemia (CML) patients in 1991 (23). In 2012,AXL
was found to be fused to MAP3K12 binding inhibitory protein 1
(MBIP) resulting in AXL-MBIP fusion variant by whole genome
sequencing (WGS) (3). In the same study, Seo et al. also discovered
the platelet derived growth factor receptor-alpha (PDGFR-α) was
fused to SR-related CTD-associated factor 11 (SCAF11-PDGFR-
α) in NSCLC (3). Prior to that, rearrangement in PGDFR-α was
found in myeloid and lymphoid neoplasms with esinophilia where
PDGFR-α is fused to Flip1-like 1 gene (FIP1L1) (FIP1L1-PDGFR-
α) (24). Interesting aberrantly activation by phosphorylation of
PDGFR-α was demonstrated in one cell line (H1703) and several
patient samples in 2007 but no rearrangement was discovered (13).
In summary, many of the RTK-rearrangements in NSCLC were
discovered in other tumors but because of the success of crizotinib
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Table 1 | Characteristics of RTK rearrangement in NSCLC.
RTK
rearrangement
Year
identified
Fusion partners Estimate
prevalence (%)
Methods of initial
identification
Select reference
ALK 2007 EML4-, KIF5B-, KCL-, TFG- ~5–8 Tumor DNA transfection,
Phospho-kinase activation
Ou et al. (1)
ROS1 2007 CD74-, SDC4-, SLC34A2-,TPM3-, FIG-,
KDEL2-, CCDC6-, LRIG3-, ERZ-
~2 Phospho-kinase activation Gainor and Shaw (2)
RET 2012 KIF5B-, CCDC6-, NOCA4-, TRIM33- ~2 FISH, NGS, WGS Gainor and Shaw (2)
AXL 2012 MBIP- NA WGS Seo et al. (3)
PDGFR-α 2012 SCAF11- NA WGS Seo et al. (3)
NTRK1 2013 CD74-, MPRIP- ~3a FISH, NGS Vaishnavi et al. (4)
a3.3% in ALK, ROS1, RET negative NSCLC.
the discovery of these RTK-rearrangements in NSCLC has drawn
increased attention to these RTKs in all tumor types (25).
ALK INHIBITORS FOR THE TREATMENT OF ALK- AND
ROS1-REARRANGED NSCLC
While crizotinib is the first and only ALK inhibitor approved for
the treatment of advanced ALK -rearranged NSCLC since August
2011, the majority of patients invariably progress on crizotinib
with a median progression-free survival of about 8 months (26).
The incorporation of break-apart ALK FISH as the FDA-approved
CDx for detection of ALK rearrangement through the approval
of crizotinib has provided a new standard of care with an estab-
lished assay to screen for and enroll theseALK -rearranged NSCLC
patients onto clinical trials of these ALK inhibitors. Pfizer, the
manufacturer of crizotinib, engaged a diagnostic company to sup-
port both the development and technical validation of the ALK
FISH CDx. In this case, Abbott Molecular sponsored the ALK
FISH screening test and the validity of the CDx and the regulatory
approval of the CDx as well as all screening of patients, to support
the drug approval but Pfizer paid for everything Abbott Molecular.
In retrospect, Pfizer essentially paved the way for competitors to
more easily develop follow-on ALK inhibitors by establishing the
clinical validity of a CDx test and screening for ALK -rearranged
NSCLC patients. This realization, we believe has important impli-
cations on how the CDx for the other unique RTK-rearranged
NSCLC may be developed by pharmaceutical companies.
Crizotinib has also shown significant clinical activity in ROS1-
rearranged NSCLC due to the homology between the kinase
domain (27). As part of the original phase I crizotinib trial
(PROFILE1001, NCT00585195), the assay for the trial to detect
ROS1-rearrangement is a locally developed laboratory-based test
and no formal CDx is being developed for FDA approval in
conjunction with the trial. In order for Pfizer to gain formal
FDA approval for crizotinib in ROS1-rearranged NSCLC, Pfizer
may have to sponsor another large scale trial and more impor-
tantly pay for the screening and analytical and clinical valida-
tion of a ROS1 CDx (likely be FISH again) so that a CDx can
be submitted simultaneously for FDA approval in support for
the clinical activity of crizotinib in ROS1-rearranged NSCLC.
However, once a CDx for ROS1-rearrangement is approved by
the US FDA, other pharmaceutical companies can take advan-
tage of the existence of an FDA-approved ROS1 CDx to develop
their own ROS1 inhibitors similarly to the situations for current
ALK inhibitors in clinical development. Given the low incidence of
ROS1-rearranged NSCLC (~2%), Pfizer or other pharmaceutical
companies is unlikely to make this investment given crizotinib
is already available in many countries. Furthermore, although
many Clinical Laboratory Improvement Amendments (CLIA)-
certified commercial diagnostic companies in the US are offering
ROS1-rearrangement testing [either by break-apart FISH, reverse
transcription-polymerase chain reaction (RT-PCR), or even next
generation sequencing (NGS)], without an official indication from
the US FDA, screening for ROS1-rearrangement among commu-
nity oncologists in the US will not be a common practice. With-
out an official FDA indication of crizotinib for ROS1-rearranged
NSCLC, even with the endorsement of the National Compre-
hensive Cancer Centers Network (NCCN) guidelines, insurance
companies may not pay for crizotinib for the few ROS1-positive
NSCLC patients, even if their oncologists prescribe it. Further-
more, without an FDA indication for ROS1-rearranged NSCLC,
the research of ROS1-rearrangement in other major epithelial
tumor types such as colon (17) and gastric cancer (16), the cost of
co-developing a companion diagnostics for ROS1-rearrangement
will dissuade a lot of pharmaceutical companies to pursue a regis-
tration strategy in any ROS1-rearranged tumors even if they have
potent ROS1 inhibitors in the pipeline.
WILL A RET INHIBITOR EVER BE FORMALLY APPROVED BY
THE US FDA FOR RET -REARRANGED NSCLC ANDWHAT IS
THE IMPLICATION IF THE ANSWER IS NO?
We ask this question because the clinical reality of RET -rearranged
NSCLC is even more relevant in illustrating the central theme of
this perspective. There are currently at least six marketed TKIs
(regorafenib, cabozantinib, ponatinib, sunitinib, sorafenib, van-
detanib) in the US that are also potent in vitro RET inhibitors
(Table 2). Under the current US FDA regulations, manufacturers
of any one of the above marketed TKIs who wants to gain an addi-
tional approval for treatment of RET -rearranged NSCLC will have
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to pay for the screening for thousands of NSCLC patients and the
development of a RET -rearrangement CDx. Again given the low
incidence of RET -rearranged of NSCLC (~2%) and the potential
crowded market for RET inhibitors, it is unlikely manufacturer of
any one of the six potential marketed RET inhibitors will sponsor
such as a trial, lest it will allow competitors to piggyback on the
CDx to gain approval of their TKIs without shouldering the cost
for patient screening and developing an approvable CDx. This is
currently, the case as all the clinical trials in these marketed TKIs are
investigator-initiated trials with a diverse platforms to screen for
RET rearrangement (Table 2). Indeed, preliminary clinical activ-
ity of cabozantinib in three RET -rearranged NSCLC patients has
been recently published (28). The exception is the manufacturer of
lenvatinib (E7080) (Eisai Company, Ltd.) who is sponsoring a trial
of lenvatinib in RET -rearranged NSLCL primarily in Asia using
NGS as the primary CDx (NCT01829217) (Table 2). Without a US
FDA-approved RET CDx, not only will potential RET inhibitors
not gain US FDA approval to treat RET -rearranged NSCLC but
other RET -rearranged malignancies such as thyroid cancer (19)
or chronic myelomonocytic leukemia (CMML) (29).
Going forward, many small molecular inhibitors are being
developed against AXL (30) and NTRK1 (31, 32). Additionally,
imatinib has shown excellent clinical activity against myeloid and
lymphoid malignancies harboring FIP1L1-PDGFR-α rearrange-
ment (33). Thus, achieving the goal of precision cancer medicine
hinges on formal approval of these inhibitors to treat these various
rare but diverse molecularly defined and driven malignancies and
the requirement to co-develop a CDx may be a huge impediment
to achieving this goal.
IS THE FIRST APPROVED CDx THE BEST CDx CONSIDERING
THE ISSUES OF COST-EFFECTIVENESS, KNOWLEDGE
ADVANCEMENT, AND TECHNOLOGY OBSOLESCENCE?
The approval of the Abbott Vysis break-apart FISH assay by the
FDA as the CDx for the diagnosis of ALK -rearranged NSCLC
seemed to have established break-apart FISH as the lead method
platform to diagnose RTK rearrangement in NSCLC. However,
break-apart FISH is probably “the worst of both worlds” as a CDx
platform. There are three major criteria that have to be satisfied for
a break-apart FISH to be considered positive: (1) a minimum of 50
cells have to be counted; (2) signals are considered “break-apart”
when they are separated by at least two diameter in length OR only
the 3′ signal is present; (3) at least 15% of the cells have to contain
the break-apart signals. Polysomy is common in ALK -rearranged
lung cancer tumor (34) thus, identifying all these criteria requires
technical expertise and expert interpretation and is labor-intensive
and time consuming. Additionally, FISH is prohibitively expensive
as a mass screening method for many countries. Finally, FISH will
not identify the specific fusion partner to the rearranged RTK
gene. As our knowledge about RTK-rearranged NSCLC grows, it
is highly likely that different RTK fusion variant will have different
clinicopathologic characteristics such as extent of disease, site of
metastasis, and differential response to TKIs (35), which required
even more tailored treatment in the future. In summary, FISH
is neither an inexpensive mass screening CDx nor does it lead
to further understanding of the pathogenesis of RTK-rearranged
NSCLC.
In contrast, ALK protein is only expressed in tumor tissue due
to transcriptional activation from the promoter of the 5′-fusion
partner to ALK but not in normal tissue and can be easily detected
by immunohistochemistry (IHC). IHC is inexpensive and easily
performed by all pathologists. Furthermore, ALK IHC has been
demonstrated to show high concordance to ALK FISH (36). Since
October 2012, IHC (Ventana automated staining system using
D5F3 antibody from Cell Signaling Inc.) has been approved in
the European Union (EU) as a CDx to detect ALK rearrangement
along with break-apart FISH. This automated ALK IHC stain-
ing platform has shown extremely high sensitivity and specificity
to ALK FISH (37). In September 2013 China approved the same
method approved in EU to detect ALK rearrangement.
Immunohistochemistry has been used to detect ROS1-
rearrangement in NSCLC and the sensitivity and specificity of
ROS1 IHC is found to be 100 and 92%, respectively (38). Thus,
it is likely with further refinement, IHC will likely be widely used
to detect ROS1-rearrangement. On the other hand, RET is highly
expressed in normal tissue and the sensitivity of RET IHC is low
and thus, IHC may not be an ideal CDx to diagnoseRET rearrange-
ment (39). Thus, while IHC is a standard pathology procedure and
cheaper than FISH, it is not applicable to all the different RTK-
rearrangements depending on the normal expression pattern of
the RTK in that particular tumor type. Much remain to be discov-
ered on the expression level of TRK1-,AXL-, and PDGFRα- fusion
proteins in NSCLC before we can really assess the utility of IHC
in the detecting of these newly discovered molecular subtypes of
RTK-rearranged NSCLC.
Reverse transcription-polymerase chain reaction is another
commonly utilized research technique to detect RTK rearrange-
ment. RT-PCR is highly specific and can be easily performed
in standard diagnostic laboratories. However, most of the RT-
PCR studies require large volume of tumor tissue snapped frozen
from surgical resection. In daily oncology practice, the vast
majority of the NSCLC are diagnosed from fine or core needle
biopsy from which the tissue is placed in formalin instead of
snap frozen at −80°C. RNA is not easily preserved in formalin-
fixed tissues and thus RT-PCR may not be technically feasible
in many of the samples. Also given that each unique mole-
cular subtype of RTK-rearranged NSCLC has many different
fusion variants; in order to identify all the known fusion vari-
ants the PCR has to contain primers to all the fusion partners.
Any un-reported/un-discovered fusion partner will be missed
by RT-PCR. In the case of ROS1-rearrangement, at least nine
sets of primers for the nine reported fusion partners have to be
present in the RT-PCR. Therefore, although RT-PCR has been
commercialized in the US to detect RTK-rearranged NSCLC (40),
it is not a widely adopted CDx and unlikely to gain global
acceptance.
Next generation sequencing is a broad term that generally
describes the massively parallel sequencing approach and employ-
ing various detection methods on a panel of genes that are altered
in cancer. Many NGS panels of varying number of gene are now
being offered commercially. For example, Foundation Medicine
Inc., is offering a 236 gene test that can detect mutations, copy
number alterations, and 19 gene rearrangements that has been
used commercially used to detect new RET rearrangement in
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an investigator-initiated trial (28) or previously undetected ALK
rearrangement (41).
Advances in the understanding of neoplastic diseases couple
with technical advancement in the field of diagnostic tests raise
the ongoing issue of technology obsolescence supporting the orig-
inal FDA-approved test. Technology obsolescence will invariably
poses a significant problem with time because one particular tech-
nology/diagnostic platform (i.e., FISH) is essentially linked to drug
labeling by the FDA. With time that one specific diagnostic plat-
form may turn out to be expensive,highly operator dependent with
a steep learning curve, not easily automatable, and provide scant
clinical information (e.g., FISH does not provide the fusion part-
ner nor the break-point, which may be important in underlying
the clinicopathologic and natural history of that particular RTK
rearrangement). The ideal future CDx should be able to pinpoint
chromosomal breakpoint and to identify the various fusion part-
ners to a particular RTK rearrangement so that, we can continue
to advance our molecular understanding of oncology in order to
refine our approach to personalized medicine.
However, to get a different CDx platform approved by the FDA
will again incur significant expense not only in standardization and
validation of the new CDx but the cost of conducting a clinical trial
“reinventing” the original approval process.
SAMPLE SURVEY OF THE APPROVED INDICATIONS FOR
CRIZOTINIB OUTSIDE THE US
Crizotinib received conditional approval in the EU in July 2012 for
previously treated ALK-positive NSCLC with the recommenda-
tion that a validated test forALK rearrangement be used. Similarly
crizotinib was approved in Singapore in 2013 for the treatment of
locally advanced or metastatic ALK -rearranged NSCLC detected
by an accurate and validated test. However, no one particular CDx
(such as FISH) was specified by the approval in both EU and Sin-
gapore. Granted that in EU the approval of medicines and CDx
are coordinated by two different agencies (42). Indeed, since Octo-
ber 2012, Vetana ALK IHC has been approved as a CDx for ALK
rearrangement also. In Korea (2012), Japan (2012), and Australia
(2013), crizotinib was approved for treatment of ALK -rearranged
NSCLC without mention of the detection method. Granted by
2012, there is plentiful data supporting high concordance FISH
and IHC (36) or even NGS (41) thus it is not necessary to pigeon-
hole a drug approval to one particular CDx. However, without
the initial US FDA approval of crizotinib and the advance in
knowledge over the intervening years it is likely that “relaxed”
CDx requirement will not be possible in many countries. Thus,
approval of the US FDA remains the gold standard for the drug
regulatory agencies and authorities in many countries.
CONCLUDING PERSPECTIVES
Many of the RTKs discussed in this perspective were discovered
in 1980s as transformed oncogenes due to elegant basic science
research. It has been more than 30 years since then to now where
we are at the cusp of realizing precision cancer medicine by suc-
cessfully translating these discoveries to therapeutic approvals and
finally bearing fruit of all the research funding for the benefit of
patients. The successful launch of crizotinib has been an inspiring
example of this development.
The technologies to screen for these RTKs in all tumors are com-
mercially available; inhibitors to these RTKs are either approved
for other indication or in early clinical development. Because of
the rarity of these RTK-rearrangements, the cost of sponsoring a
registration trial for a particular TKI and simultaneous develop-
ment of a CDx is prohibitively expensive and clinical progress is
being delayed due to reluctance of pharmaceutical companies to
pursue such narrow indications in rare disease populations.
One attractive though organizationally challenging solution
may be to foster a collaboration of government, pharmaceutical
companies, and diagnostic companies pooling resources together
to an independent consortium to establish analytical and clinical
validity of CDx platforms for detection of RTK-rearrangements
and potentially other cancer genes. The US FDA may then approve
these CDx platforms such as FISH, IHC, or NGS for each or
several RTK-rearrangements and then allowing pharmaceutical
companies to sponsor the trials and select any of the CDx plat-
forms to demonstrate clinical benefit. This will alleviate the burden
of simultaneously developing a CDx that can then be “piggy-
backed” by other pharmaceutical companies developing their
own inhibitors. Additionally, this will eliminate potential conflict
of interest as some global pharmaceutical companies also own
major diagnostic companies (i.e., Ventana Medical Systems by F.
Hoffmann-La Roche, Genoptix by Novartis) where one partic-
ular diagnostic platform may be favored by one pharmaceutical
company due to technological knowhow and/or existing patents.
Short of industry-wide cooperation, regulatory policy may be
used to lower regulatory burdens and create a more favorable
incentive structure for therapeutic and diagnostics companies
pursuing targeted therapy and CDx development. For instance,
to reduce CDx costs, certain CDx quality systems and validation
requirements may be simplified or deferred to the post-approval
period, given appropriate risk determination. And as above, some
assays may be approvable based on analytical validation data alone,
decoupling diagnostic from therapeutic development decisions
and thus streamlining coordination.
The requirement for co-development and co-approval of CDx
in order to get TKIs approved against these RTK (ROS1, RET,
NTRK1, AXL, PDGFR-α) rearrangement lung cancer represents
the daunting challenge to successfully translate decades of basic
science research into benefit of cancer patients. However, the suc-
cessful approval of TKIs to treatROS1-,RET-,NTRK1-, PDGFR-α,
and AXL-rearranged NSCLC is vitally important as it sets the
example for approval of TKIs to treat the same RTK-rearranged
common epithelial tumors such as colon, gastric, and breast can-
cers (25). Using NSCLC as a tumor example, we wish this per-
spective contributed to the ongoing in-depth discussions about
how to optimally and expeditiously develop TKIs to receive US
FDA approval in the current regulatory environment where co-
development and co-approval of a CDx is required for a drug in
other TK-driven cancers.
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